695 related articles for article (PubMed ID: 25694607)
1. Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection.
van Diepen A; Brand HK; de Waal L; Bijl M; Jong VL; Kuiken T; van Amerongen G; van den Ham HJ; Eijkemans MJ; Osterhaus AD; Hermans PW; Andeweg AC
J Virol; 2015 May; 89(9):5022-31. PubMed ID: 25694607
[TBL] [Abstract][Full Text] [Related]
2. Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease.
Su YC; Townsend D; Herrero LJ; Zaid A; Rolph MS; Gahan ME; Nelson MA; Rudd PA; Matthaei KI; Foster PS; Dent L; Tripp RA; Lee J; Simson L; Mahalingam S
J Virol; 2015 Feb; 89(3):1564-78. PubMed ID: 25410867
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
[TBL] [Abstract][Full Text] [Related]
4. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of STAT6 during vaccination with formalin-inactivated RSV prevents induction of Th2-cell-biased airway disease.
Srinivasa BT; Fixman ED; Ward BJ
Eur J Immunol; 2014 Aug; 44(8):2349-59. PubMed ID: 24796717
[TBL] [Abstract][Full Text] [Related]
6. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
[TBL] [Abstract][Full Text] [Related]
7. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
[TBL] [Abstract][Full Text] [Related]
8. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
[TBL] [Abstract][Full Text] [Related]
9. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
Shafique M; Wilschut J; de Haan A
Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195
[TBL] [Abstract][Full Text] [Related]
10. IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease.
Castilow EM; Meyerholz DK; Varga SM
J Immunol; 2008 Feb; 180(4):2376-84. PubMed ID: 18250447
[TBL] [Abstract][Full Text] [Related]
11. Virus-like particle vaccine primes immune responses preventing inactivated-virus vaccine-enhanced disease against respiratory syncytial virus.
Hwang HS; Lee YT; Kim KH; Ko EJ; Lee Y; Kwon YM; Kang SM
Virology; 2017 Nov; 511():142-151. PubMed ID: 28846899
[TBL] [Abstract][Full Text] [Related]
12. A Recombinant G Protein Plus Cyclosporine A-Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease.
Li C; Zhou X; Zhong Y; Li C; Dong A; He Z; Zhang S; Wang B
J Immunol; 2016 Feb; 196(4):1721-31. PubMed ID: 26792805
[TBL] [Abstract][Full Text] [Related]
13. The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia.
Olson MR; Hartwig SM; Varga SM
J Immunol; 2008 Dec; 181(11):7958-68. PubMed ID: 19017987
[TBL] [Abstract][Full Text] [Related]
14. Nonglycosylated G-Protein Vaccine Protects against Homologous and Heterologous Respiratory Syncytial Virus (RSV) Challenge, while Glycosylated G Enhances RSV Lung Pathology and Cytokine Levels.
Fuentes S; Coyle EM; Golding H; Khurana S
J Virol; 2015 Aug; 89(16):8193-205. PubMed ID: 26018164
[TBL] [Abstract][Full Text] [Related]
15. Unveiling Integrated Functional Pathways Leading to Enhanced Respiratory Disease Associated With Inactivated Respiratory Syncytial Viral Vaccine.
Russell MS; Creskey M; Muralidharan A; Li C; Gao J; Chen W; Larocque L; Lavoie JR; Farnsworth A; Rosu-Myles M; Hashem AM; Yauk CL; Cao J; Van Domselaar G; Cyr T; Li X
Front Immunol; 2019; 10():597. PubMed ID: 30984178
[TBL] [Abstract][Full Text] [Related]
16. A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats.
Kamphuis T; Stegmann T; Meijerhof T; Wilschut J; de Haan A
Influenza Other Respir Viruses; 2013 Nov; 7(6):1227-36. PubMed ID: 23575113
[TBL] [Abstract][Full Text] [Related]
17. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease.
Castilow EM; Olson MR; Varga SM
Immunol Res; 2007; 39(1-3):225-39. PubMed ID: 17917067
[TBL] [Abstract][Full Text] [Related]
18. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS
PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508
[TBL] [Abstract][Full Text] [Related]
19. Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model.
Passmore C; Makidon PE; O'Konek JJ; Zahn JA; Pannu J; Hamouda T; Bitko V; Myc A; Lukacs NW; Fattom A; Baker JR
Hum Vaccin Immunother; 2014; 10(3):615-22. PubMed ID: 24326268
[TBL] [Abstract][Full Text] [Related]
20. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice.
Boelen A; Andeweg A; Kwakkel J; Lokhorst W; Bestebroer T; Dormans J; Kimman T
Vaccine; 2000 Nov; 19(7-8):982-91. PubMed ID: 11115725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
